메뉴 건너뛰기




Volumn 79, Issue 2, 2010, Pages 129-130

Is memory impairment a rate limiter in cognitive behavioural therapy for chronic schizophrenia?

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; OLANZAPINE; RISPERIDONE;

EID: 74249117086     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276378     Document Type: Letter
Times cited : (10)

References (6)
  • 1
    • 0037290135 scopus 로고    scopus 로고
    • Neurocognition and community outcome in schizophrenia: Long-term predictive validity
    • Fujii DE, Wylie AM: Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophr Res 2002; 59: 219-223.
    • (2002) Schizophr Res , vol.59 , pp. 219-223
    • Fujii, D.E.1    Wylie, A.M.2
  • 2
    • 0037114868 scopus 로고    scopus 로고
    • Schizophrenia and memory impairment: Evidence for a neurocognitive subtype
    • McDermid SA, Heinrichs RW: Schizophrenia and memory impairment: evidence for a neurocognitive subtype. Psychiatry Res 2002;113: 93-105.
    • (2002) Psychiatry Res , vol.113 , pp. 93-105
    • McDermid, S.A.1    Heinrichs, R.W.2
  • 3
    • 14644406096 scopus 로고    scopus 로고
    • Cognitive behaviour therapy for schizophrenia-a review of development, evidence and implementation
    • Tarrier N: Cognitive behaviour therapy for schizophrenia-a review of development, evidence and implementation. Psychother Psychosom 2005; 74:136-144.
    • (2005) Psychother Psychosom , vol.74 , pp. 136-144
    • Tarrier, N.1
  • 6
    • 0001779422 scopus 로고    scopus 로고
    • The contribution of reliable and clinically significant change methods to evidence-based mental health
    • Evans C, Margison F, Barkham M: The contribution of reliable and clinically significant change methods to evidence-based mental health. Evid Based Ment Health 1998; 1:7 0-7 2.
    • (1998) Evid Based Ment Health , vol.1 , pp. 70-72
    • Evans, C.1    Margison, F.2    Barkham, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.